GlassScriptPhysician profile
Dana Henderson
NPI 1508868811
$1,714.48
in general payments reported to CMS, 2019-2025
15 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $226 · 2023: $359 · 2024: $405 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.28 | 2021-2025 | |
| Pfizer INC. | $454.01 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $102.70 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $80.91 | 2024 | Breztri |
| Glaxosmithkline, LLC. | $77.26 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $70.66 | 2025 | Austedo Xr |
| Novo Nordisk INC | $35.90 | 2021-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $34.31 | 2024-2025 | Rexulti |
| Hologic Sales and Service, LLC | $27.50 | 2021 | |
| Merck Sharp & Dohme LLC | $19.98 | 2021 | |
| Boston Scientific Corporation | $18.12 | 2023 | Watchman Flx |
| Sunovion Pharmaceuticals INC. | $15.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.62 | 2022 | |
| Urovant Sciences INC | $14.23 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.